Princess Alexandra
Welcome,         Profile    Billing    Logout  
 8 Trials 
14 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walpole, Euan T
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Germ Cell Tumor
12/29
12/29
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
3
614
Canada, RoW
Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited
Unresectable/Metastatic Melanoma
12/27
12/29
CHALLENGE, NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Grimison, Peter
ACTRN12613000496718: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Recruiting
3
500
 
University of Sydney, Cancer Australia
Intermediate and poor-risk metastatic germ cell tumours (GCTs)
 
 
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Germ Cell Tumor
12/29
12/29
ACTRN12618001236280: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Active, not recruiting
3
420
 
Alliance for Clinical Trials in Oncology, Australian and New Zealand Urogenital and Prostate Cancer Trials (ANZUP)
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma, Cancer
 
 
NCT02375204: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active, not recruiting
3
420
Europe, US, RoW
paclitaxel, Taxol, ifosfamide, Ifex®, IFOS, cisplatin, CDDP, pegylated G-CSF, G-CSF, carboplatin, Paraplatin®, CBDCA, etoposide phosphate, VePesid®, Toposar®, VP16, stem cell reinfusion
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Cancer Research UK, UNICANCER, Irish Group CTI
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
06/31
06/31
STRASS 2, NCT04031677: Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Recruiting
3
250
Europe, Canada, Japan, US, RoW
Surgery, Preoperative chemotherapy, neoadjuvant chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, Anticancer Fund, Belgium, Australia and New Zealand Sarcoma Association, Japan Clinical Oncology Group
Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
04/27
04/28
ACTRN12616001036404: CannabisCINV: A placebo-controlled trial evaluating an oral THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting in patients of any known malignancy receiving chemotherapy.

Terminated
2/3
250
 
University of Sydney, Health Administration Corporation, through the NSW Ministry of Health, for and on behalf of the NSW Government, Tilray
Chemotherapy induced nausea and vomiting, Cancer
 
 
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Terminated
2/3
359
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
07/24
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
ACTRN12607000294459: “Accelerated BEP” A feasibility study of accelerated BEP as first line chemotherapy for advanced germ cell tumours

Active, not recruiting
1/2
45
 
The University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Cancer Council NSW, VIC, SA and QLD.
First Line Chemotherapy for Advanced Germ Cell Tumours
 
 
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
NCT05653388: Metastatic Leiomyosarcoma Biomarker Protocol

Recruiting
N/A
200
US, RoW
Plasma Collection
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Leiomyosarcoma
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walpole, Euan T
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Germ Cell Tumor
12/29
12/29
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
3
614
Canada, RoW
Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited
Unresectable/Metastatic Melanoma
12/27
12/29
CHALLENGE, NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Grimison, Peter
ACTRN12613000496718: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Recruiting
3
500
 
University of Sydney, Cancer Australia
Intermediate and poor-risk metastatic germ cell tumours (GCTs)
 
 
P3BEP, NCT02582697 / 2015-003060-37 / ACTRN12613000496718: Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Recruiting
3
500
US, RoW
Bleomycin (active name: Bleomycin Sulfate), Blenamax (Aspen), DBL Bleomycin Sulphate (Willow Pharmaceuticals Pty Limited), Bleo Powder for injection (Hospira), Etoposide, DBL Etoposide Injection (Hospira), Etopophos (Bristol-Myers Squibb), Etoposide (Pfizer), Etoposide Ebewe (Sandoz), Cisplatin, Cisplatin Ebewe (Sandoz), Cisplatin injection (Pfizer), DBL Cisplatin Injection (Hospira), Pegylated G-CSF (Pegfilgrastim), Neulasta Syringe with Automatic Needle Guard (Amgen), Filgrastim, Neupogen (Amgen), Nivestim (Hospira), Tevagrastim (Teva Pharma Australia Pty Ltd), Zarzio (Sandoz)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Germ Cell Tumor
12/29
12/29
ACTRN12618001236280: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Active, not recruiting
3
420
 
Alliance for Clinical Trials in Oncology, Australian and New Zealand Urogenital and Prostate Cancer Trials (ANZUP)
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma, Cancer
 
 
NCT02375204: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active, not recruiting
3
420
Europe, US, RoW
paclitaxel, Taxol, ifosfamide, Ifex®, IFOS, cisplatin, CDDP, pegylated G-CSF, G-CSF, carboplatin, Paraplatin®, CBDCA, etoposide phosphate, VePesid®, Toposar®, VP16, stem cell reinfusion
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Cancer Research UK, UNICANCER, Irish Group CTI
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
06/31
06/31
STRASS 2, NCT04031677: Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Recruiting
3
250
Europe, Canada, Japan, US, RoW
Surgery, Preoperative chemotherapy, neoadjuvant chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, Anticancer Fund, Belgium, Australia and New Zealand Sarcoma Association, Japan Clinical Oncology Group
Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
04/27
04/28
ACTRN12616001036404: CannabisCINV: A placebo-controlled trial evaluating an oral THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting in patients of any known malignancy receiving chemotherapy.

Terminated
2/3
250
 
University of Sydney, Health Administration Corporation, through the NSW Ministry of Health, for and on behalf of the NSW Government, Tilray
Chemotherapy induced nausea and vomiting, Cancer
 
 
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Terminated
2/3
359
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
07/24
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
ACTRN12607000294459: “Accelerated BEP” A feasibility study of accelerated BEP as first line chemotherapy for advanced germ cell tumours

Active, not recruiting
1/2
45
 
The University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Cancer Council NSW, VIC, SA and QLD.
First Line Chemotherapy for Advanced Germ Cell Tumours
 
 
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
NCT05653388: Metastatic Leiomyosarcoma Biomarker Protocol

Recruiting
N/A
200
US, RoW
Plasma Collection
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Leiomyosarcoma
12/26
12/26

Download Options